B. Rosenberg, L. Vancamp, and T. Krigas, Inhibition Of Cell Division In Escherichia Coli By Electrolysis Products From A Platinum Electrode, Nature. 13 févr, vol.205, pp.698-707, 1965.

T. A. Connors, M. Jones, W. C. Ross, P. D. Braddock, A. R. Khokhar et al., New platinum complexes with anti-tumour activity, Chem Biol Interact. nov, vol.5, issue.6, pp.415-439, 1972.

T. W. Hambley, The influence of structure on the activity and toxicity of Pt anti-cancer drugs, Coord Chem Rev, vol.166, pp.181-223, 1997.

. Pubchem, , 2017.

. Disponible,

. Pubchem, , 2017.

. Disponible,

M. Pavelka, M. Lucas, and N. Russo, On the hydrolysis mechanism of the secondgeneration anticancer drug carboplatin, Chem Weinh Bergstr Ger, vol.13, issue.36, pp.10108-10124, 2007.

F. A. Blommaert, H. C. Van-dijk-knijnenburg, F. J. Dijt, L. Den-engelse, R. A. Baan et al., Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells, Biochemistry (Mosc). 4 juill, vol.34, issue.26, pp.8474-80, 1995.

R. S. Go and A. A. Adjei, Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin, J Clin Oncol Off J Am Soc Clin Oncol. janv, vol.17, issue.1, pp.409-431, 1999.

R. C. Todd and S. J. Lippard, Inhibition of transcription by platinum antitumor compounds, Met Integr Biometal Sci, vol.1, issue.4, pp.280-91, 2009.

M. Kartalou and J. M. Essigmann, Recognition of cisplatin adducts by cellular proteins, Mutat Res. 1 juill, vol.478, issue.1-2, pp.1-21, 2001.

L. P. Martin, T. C. Hamilton, and R. J. Schilder, Platinum resistance: the role of DNA repair pathways, Clin Cancer Res Off J Am Assoc Cancer Res. 1 mars, vol.14, issue.5, pp.1291-1296, 2008.

, der Vijgh WJ, vol.21, pp.242-61, 1991.

F. Elferink, W. J. Van-der-vijgh, I. Klein, J. B. Vermorken, H. E. Gall et al., Pharmacokinetics of carboplatin after i.v. administration, Cancer Treat Rep. déc, vol.71, issue.12, pp.1231-1238, 1987.

A. H. Calvert, D. R. Newell, L. A. Gumbrell, S. O'reilly, M. Burnell et al., Carboplatin dosage: prospective evaluation of a simple formula based on renal function, J Clin Oncol Off J Am Soc Clin Oncol, vol.7, issue.11, pp.1748-56, 1989.

A. H. Calvert, S. J. Harland, D. R. Newell, Z. H. Siddik, A. C. Jones et al., Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II, Cancer Chemother Pharmacol, vol.9, issue.3, pp.140-147, 1982.

D. I. Jodrell, M. J. Egorin, R. M. Canetta, P. Langenberg, E. P. Goldbloom et al., Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer, J Clin Oncol Off J Am Soc Clin Oncol. avr, vol.10, issue.4, pp.520-528, 1992.

A. Schmitt, L. Gladieff, C. M. Laffont, A. Evrard, J. Boyer et al., Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure, J Clin Oncol Off J Am Soc Clin Oncol, vol.28, issue.30, pp.4568-74, 2010.

M. J. Egorin, D. A. Van-echo, E. A. Olman, M. Y. Whitacre, A. Forrest et al., Prospective validation of a pharmacologically based dosing scheme for the cisdiamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum, Cancer Res. déc, vol.45, issue.12, pp.6502-6508, 1985.

E. Chatelut, P. Canal, V. Brunner, C. Chevreau, A. Pujol et al., Prediction of carboplatin clearance from standard morphological and biological patient characteristics, J Natl Cancer Inst. 19 avr, vol.87, issue.8, pp.573-80, 1995.

F. Thomas, S. Séronie-vivien, L. Gladieff, F. Dalenc, V. Durrand et al., Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin, Clin Pharmacokinet, vol.44, issue.12, pp.1305-1321, 2005.

R. D. Perrone, N. E. Madias, and A. S. Levey, Serum creatinine as an index of renal function: new insights into old concepts, Clin Chem. oct, vol.38, issue.10, pp.1933-53, 1992.

A. C. Baxmann, M. S. Ahmed, N. C. Marques, V. B. Menon, A. B. Pereira et al., Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C, Clin J Am Soc Nephrol CJASN. mars, vol.3, issue.2, pp.348-54, 2008.

V. R. Dharnidharka, C. Kwon, and G. Stevens, Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis, Am J Kidney Dis Off J Natl Kidney Found. août, vol.40, issue.2, pp.221-227, 2002.

L. A. Inker, C. H. Schmid, H. Tighiouart, J. H. Eckfeldt, H. I. Feldman et al., Estimating glomerular filtration rate from serum creatinine and cystatin C, N Engl J Med. 5 juill, vol.367, issue.1, pp.20-29, 2012.

A. Schmitt, L. Gladieff, A. Lansiaux, C. Bobin-dubigeon, E. Boisdron-celle et al., A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients, Clin Cancer Res Off J Am Assoc Cancer Res. 15 mai, vol.15, issue.10, pp.3633-3642, 2009.

A. Moses, C. Slater, T. Preston, M. D. Barber, and K. Fearon, Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids, Br J Cancer. 8 mars, vol.90, issue.5, pp.996-1002, 2004.

J. Bachmann, M. Heiligensetzer, H. Krakowski-roosen, M. W. Büchler, H. Friess et al., Cachexia worsens prognosis in patients with resectable pancreatic cancer, J Gastrointest Surg Off J Soc Surg Aliment Tract. juill, vol.12, issue.7, pp.1193-201, 2008.

W. D. Dewys, C. Begg, P. T. Lavin, P. R. Band, J. M. Bennett et al., Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group, Am J Med. oct, vol.69, issue.4, pp.491-498, 1980.

K. Fearon, F. Strasser, S. D. Anker, I. Bosaeus, E. Bruera et al., Definition and classification of cancer cachexia: an international consensus, Lancet Oncol. mai, vol.12, issue.5, pp.489-95, 2011.

R. A. Fielding, B. Vellas, W. J. Evans, S. Bhasin, J. E. Morley et al., Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia, J Am Med Dir Assoc. mai, vol.12, issue.4, pp.249-56, 2011.

A. J. Cruz-jentoft, J. P. Baeyens, J. M. Bauer, Y. Boirie, T. Cederholm et al., European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People, vol.39, pp.412-435, 2010.

J. Tegels, J. Van-vugt, K. W. Reisinger, K. Hulsewé, A. Hoofwijk et al., Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes, J Surg Oncol. sept, vol.112, issue.4, pp.403-410, 2015.

O. Mir, R. Coriat, P. Boudou-rouquette, S. Ropert, J. Durand et al., Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib, Med Oncol Northwood Lond Engl. déc, vol.29, issue.4, pp.2793-2802, 2012.

S. Kazemi-bajestani, V. C. Mazurak, and V. Baracos, Computed tomography-defined muscle and fat wasting are associated with cancer clinical outcomes, Semin Cell Dev Biol. juin, vol.54, pp.2-10, 2016.

R. N. Baumgartner, K. M. Koehler, D. Gallagher, L. Romero, S. B. Heymsfield et al., Epidemiology of sarcopenia among the elderly in New Mexico, Am J Epidemiol. 15 avr, vol.147, issue.8, pp.755-63, 1998.

I. Janssen, S. B. Heymsfield, and R. Ross, Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability, J Am Geriatr Soc. mai, vol.50, issue.5, pp.889-96, 2002.

C. Prado, J. R. Lieffers, L. J. Mccargar, T. Reiman, M. B. Sawyer et al., Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol. juill, vol.9, issue.7, pp.629-664, 2008.

M. Mourtzakis, C. Prado, J. R. Lieffers, T. Reiman, L. J. Mccargar et al., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab Physiol Appliquée Nutr Métabolisme, vol.33, issue.5, pp.997-1006, 2008.

W. Shen, M. Punyanitya, Z. Wang, D. Gallagher, M. St-onge et al., Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal crosssectional image, J Appl Physiol Bethesda Md, vol.97, issue.6, pp.2333-2341, 1985.

, Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review

M. M. Oken, R. H. Creech, D. C. Tormey, J. Horton, T. E. Davis et al., Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol. déc, vol.5, issue.6, pp.649-55, 1982.

D. Bois, D. , D. Bois, and E. F. , A formula to estimate the approximate surface area if height and weight be known. 1916. Nutr Burbank Los Angel Cty Calif, vol.5, pp.312-313, 1989.

S. B. Heymsfield, Z. Wang, R. N. Baumgartner, and R. Ross, Human body composition: advances in models and methods, Annu Rev Nutr, vol.17, pp.527-58, 1997.

N. Mitsiopoulos, R. N. Baumgartner, S. B. Heymsfield, W. Lyons, D. Gallagher et al., Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography, J Appl Physiol Bethesda Md, vol.85, issue.1, pp.115-137, 1985.

S. Antoun, V. E. Baracos, L. Birdsell, B. Escudier, and M. B. Sawyer, Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma, Ann Oncol Off J Eur Soc Med Oncol ESMO. août, vol.21, issue.8, pp.1594-1602, 2010.

L. A. Stevens and A. S. Levey, Frequently Asked Questions About GFR Estimates, 2007.

J. Chew, M. Saleem, C. M. Florkowski, and P. M. George, Estimating renal function in oncology patients using cystatin C-based equations, Clin Oncol R Coll Radiol G B. juin, vol.21, issue.5, pp.425-431, 2009.
DOI : 10.1016/j.clon.2009.01.012

J. F. Roos, J. Doust, S. E. Tett, and C. Kirkpatrick, Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children-a meta-analysis, Clin Biochem. mars, vol.40, issue.5-6, pp.383-91, 2007.

J. D. Herrington, H. T. Tran, and M. W. Riggs, Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia, Cancer Chemother Pharmacol. janv, vol.57, issue.2, pp.241-248, 2006.

C. Ekhart, S. Rodenhuis, J. Schellens, J. H. Beijnen, and A. Huitema, Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?, Cancer Chemother Pharmacol. juin, vol.64, issue.1, pp.115-137, 2009.

D. Kaag, Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors, Lung Cancer Amst Neth. janv, vol.79, issue.1, pp.54-62, 2013.

M. A. Winter, K. N. Guhr, and G. M. Berg, Impact of various body weights and serum creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation, Pharmacotherapy. juill, vol.32, issue.7, pp.604-616, 2012.

T. Janowitz, E. H. Williams, A. Marshall, N. Ainsworth, P. B. Thomas et al., New Model for Estimating Glomerular Filtration Rate in Patients With Cancer, J Clin Oncol Off J Am Soc Clin Oncol. 20 août, vol.35, issue.24, pp.2798-805, 2017.

M. P. Chu, L. Mccaw, C. Stretch, C. Butts, J. Hanson et al., Development of a new equation to estimate creatinine clearance in cancer patients, Cancer Chemother Pharmacol. juill, vol.76, issue.1, pp.117-141, 2015.